Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: Prevention and therapy

Transplant Infectious Disease

Volumn 1, Issue 3, 1999, Pages 165-178

  Boeckh, M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acyclovir; Cytomegalovirus; Foscarnet; Ganciclovir; Immunotherapy; Prevention; Therapy

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; SEVIRUMAB; VIRUS DNA;

CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; POLYMERASE CHAIN REACTION;

EID: 0033188239     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010305.x     Document Type: Review

References (100)

1. ZAIA J. Cytomegalovirus infection. In: THOMAS ED, BLUME KG, FORMAN SJ, eds. Hematopoietic Cell Transplantation. Oxford: Blackwell Science, Inc., 1998: 560-583.
2. BOECKH M, BOIVIN G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998: 11: 533-554.
3. BOECKH M, LJUNGMAN P. Cytomegalovirus Infection after BMT. In: BOWDEN RA, LJUNGMAN P, PAYA CV, eds. Transplant Infections. Philadelphia: Lippincott-Raven, 1998: 215-227.
4. LIMAYE A, BOWDEN RA, MYERSON D, BOECKH M. Cytomegalovirus disease before engraftment in marrow transplant patients. Clin Infect Dis 1997: 24: 830-835.
5. BOECKH M, RIDDELL SR, CUNNINGHAM T, MYERSON D, FLOWERS M, BOWDEN RA. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. Blood 1996: 88 (Supplement 1): 302a.
6. LI CR, GREENBERG PD, GILBERT MJ, GOODRICH JM, RIDDELL SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994: 83: 1971-1979.
7. BOECKH M, GOOLEY TA, MYERSON D, CUNNINGHAM T, SCHOCH G, BOWDEN RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996: 88: 4063-4071.
8. KRAUSE H, HEBART H, JAHN G, MULLER CA, EINSELE H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997: 19: 1111-1116.
9. BOWDEN RA, DIGEL J, REED EC, MEYERS JD. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 1987: 156: 899-903.
10. LJUNGMAN P, ASCHAN J, AZINGE JN, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993: 83: 118-124.
11. ZAIA JA, FORMAN SJ. Cytomegalovirus infection in the bone marrow transplant recipient. In: RUBIN RH, ed. Infectious Disease Clinics of North America: Infection in Transplantation. Philadelphia and London: WB Saunders Co., 1995: 879-900.
12. ATKINON K, NIVISON-SMITH I, DODDS A, CONCANNON A, MILLIKEN S, DOWNS K. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant 1998: 21: 691-695.
13. NGUYEN Q, CHAMPLIN R, GIRALT S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999: 28: 618-623.
14. BOECKH M, GOOLEY T, BOWDEN RA. CMV infection and viral load after peripheral blood stem cell transplant versus marrow transplant. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Perdido Beach, AL.
15. BOECKH M. 1999. Unpublished results.
16. BACIGALUPO A, ZIKOS P, VAN LINT MT, et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exp Hematol 1998: 26: 409-414.
17. LINK H, ARSENIEV L, LJUNGMAN P, PARTY EIDW. Incidence of CMV infections after allogeneic peripheral blood progenitor cell transplantation: final evaluation of the EBMT survey. 25th Annual Meeting European Group for Blood and Marrow Transplantation, 1999, Hamburg.
18. GLUCKMAN E, ROCHA V, BOYER-CHAMMARD A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997: 337: 373-381.
19. WAGNER JE, DEFOR T, RUBINSTEIN P, KURTZBERG J. Transplantation of unrelated umbilical cord blood: outcome and analysis of risk factors. Blood 1997: 90 (Suppl 1): 398.
20. WINGARD JR, CHEN DY, BURNS WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988: 71: 1432-1437.
21. REUSSER P, FISHER LD, BUCKNER CD, THOMAS ED, MEYERS JD. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990: 75: 1888-1894.
22. LJUNGMAN P, BIRON P, BOSI A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994: 13: 209-212.
23. BOECKH M, GOOLEY TA, REUSSER P, BUCKNER CD, BOWDEN RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995: 172: 939-943.
24. ENRIGHT H, HAAKE R, WEISDORF D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993: 55: 1339-1346.
25. HOLLAND HK, DIX SP, GELLER RB, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996: 14: 1156-1164.
26. BOECKH M, STEVENS-AYERS T, BOWDEN RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996: 174: 907-912.
27. HEBART H, SCHRODER A, LOFFLER J, et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis 1997: 175: 1490-1493.
28. BOECKH M, BOWDEN RA, GOODRICH JM, PETTINGER M, MEYERS JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992: 80: 1358-1364.
29. EINSELE H, EILNINGER G, STEIDLE M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease [see comments]. Lancet 1991: 338: 1170-1172.
30. BOECKH M, HAWKINS G, MYERSON D, ZAIA J, BOWDEN RA. Plasma PCR for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with PCR using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997: 64: 108-113.
31. BRYTTING M, MOUSAVI-JAZI M, BOSTROM L, et al. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients. Transplantation 1995: 60: 961-965.
32. WOLF DG, SPECTOR SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993: 56: 330-334.
33. VAN DER BIJ W, TORENSMA R, VAN SON WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988: 25: 179-188.
34. VAN DER BIJ W, VAN SON WJ, VAN DER BERG AP, TEGZESS AM, TORENSMA R, THE TH. Cytomegalovirus (CMV) antigenemia: rapid diagnosis and relationship with CMV-associated clinical syndromes in renal allograft recipients. Transplant Proc 1989: 21: 2061-2064.
35. LJUNGMAN P, PLOTKLN SA. Workshop on CMV disease: definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995: 99: S87-S88.
36. HACKMAN RC, WOLFORD JL, GLEAVES CA, et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. Transplantation 1994: 57: 231-237.
37. LJUNGMAN P, GRIFFITH P. Definitions of cytomegalovirus infection and disease. In Multidiscipinary Approach to Understanding Cytomeglaovirus Disease. Amsterdam: Exerpta Medica, 1993.
38. CINQUE P, VAGO L, DAHL H, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 1996: 10: 951-958.
39. MEYERS JD, REED EC, SHEPP DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988: 318: 70-75.
40. PRENTICE HG, GLUCKMAN E, POWLES RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994: 343: 749-753.
41. BOECKH M, GOOLEY TA, BOWDEN RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998: 178: 1153-1157.
42. LJUNGMAN P, CAMARA R, MILPIED N, et al. A randomized study of valacyclovir as prophylaxis against CMV infection and disease in BMT recipients. 25th Annual Meeting European Group for Blood and Marrow Transplantation, Hamburg, 1999, Vol. Abstract 212.
43. GOODRICH JM, BOWDEN RA, FISHER L, KELLER C, SCHOCH G, MEYERS JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993: 118: 173-178.
44. WINSTON DJ, HO WG, BARTONI K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993: 118: 179-184.
45. SALZBERGER B, BOWDEN RA, HACKMAN R, DAVIS C, BOECKH M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease: risk factors and outcome. Blood 1997: 90: 2502-2508.
46. ATKINSON K, DOWNS K, GOLENIA M, et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol 1991: 79: 57-62.
47. ATKINSON K, ARTHUR C, BRADSTOCK K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995: 16: 401-405.
48. PRZEPIORKA D, IPPOLITI C, PANINA A, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994: 13: 461-464.
49. VON BUELTZINGSLOEWEN A, BORDIGONI P, WITZ F, et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients [published erratum appears in Bone Marrow Transplant 1994 Feb;13(2):232]. Bone Marrow Transplant 1993: 12: 197-202.
50. YAU JC, DIMOPOULOS MA, HUAN SD, et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol 1991: 47: 371-376.
51. REUSSER P, GAMBERTOGLIO JG, LILLEBY K, MEYERS JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients [see comments]. J Infect Dis 1992: 166: 473-479.
52. BACIGALUPO A, TEDONE E, VAN LINT MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994: 13: 783-788.
53. MEYERS JD, LJUNGMAN P, FISHER LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990: 162: 373-380.
54. SCHMIDT GM, HORAK DA, NILAND JC, DUNCAN SR, FORMAN SJ, ZAIA JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group [see comments]. N Engl J Med 1991: 324: 1005-1011.
55. GOODRICH JM, MORI M, GLEAVES CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991: 325: 1601-1607.
56. EINSELE H, EHNINGER G, HEBART H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995: 86: 2815-2820.
57. STOCCHI R, SZYDLO R, CRADDOCK C, et al. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease in T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant 1999: 23: 705-709.
58. LJUNGMAN P, LORE K, ASCHAN J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for preemptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996: 17: 583-587.
59. BOECKH M, BOWDEN RA, GOOLEY T, MYERSOM D, COREY L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999: 93: 1781-1782, letter.
60. VERDONCK LF, DEKKER AW, ROZENBERGARSKA M, VANDENHOEK MR. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997: 24: 901-907.
61. VLIEGER AM, BOLAND GJ, JIWA NM, et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992: 9: 247-253.
62. MORETTI S, ZIKOS P, VAN LINT MT, et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998: 22: 175-180.
63. LJUNGMAN P, EINSELE H, LEE J, et al. A randomized study comparing ganciclovir and foscarnet for preemptive therapy of CMV infection in allogeneic SCT recipients. 25th Annual Meeting European Group for Blood and Marrow Transplantation, 1999, Hamburg.
64. PRENTICE HG, GLUCKMAN E, POWLES RL, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997: 19: 129-133.
65. BOECKH M, GOOLEY T, LEISENRING W, MYERSON D, COREY L. Does high-dose acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir? - Reply. J Infect Dis 1999: 180: 572-574.
66. MEYERS JD, LESZCZYNSKI J, ZAIA JA, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983: 98: 442-446.
67. WINSTON DJ, HO WG, LIN CH, BUDINGER MD, CHAMPLIN RE, GALE RP. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. Am J Med 1984: 76: 128-133.
68. WINSTON DJ, HO WG, LIN CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987: 106: 12-18.
69. RINGDEN O, PIHLSTEDT P, VOLIN L, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987: 2: 299-305.
70. BOWDEN RA, SAYERS M, FLOURNOY N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986: 314: 1006-1010.
71. BOWDEN RA, FISHER LD, ROGERS K, CAYS M, MEYERS JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant [see comments]. J Infect Dis 1991: 164: 483-487.
72. SULLIVAN KM, KOPECKY KJ, JOCOM J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation [see comments]. N Engl J Med 1990: 323: 705-712.
73. RUUTU T, LJUNGMAN P, BRINCH L, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 1997: 19: 233-236.
74. ZIKOS P, VAN LINT MT, LAMPARELLI T, et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 1998: 83: 132-137.
75. WOLFF SN, FAY JW, HERZIG RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993: 118: 937-942.
76. BOECKH M, BOWDEN RA, CHAO NJ, et al. Randomized, placebo controlled, double-blind study of a CMV glycoprotein H-specific monoclonal antibody (MSL-109) for prevention of CMV infection after allogeneic hematopoietic stem cell transplant. 24th Annual Meeting European Group for Blood and Marrow Transplantation, 1998, Italy.
77. BOWDEN RA, SLICHTER SJ, SAYERS M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 1995: 86: 3598-3603.
78. BOECKH M, RIDDELL SR, WOOGERD P, CUNNINGHAM T, WHITE K, BOWDEN RA. Primary CMV infection via marrow: incidence, response to early treatment, CMV-specific immune response, and risk of late CMV disease 9th International Symposium on Infections in the Immunocompromised Host, 1996, Assisi, Italy.
79. REED EC, BOWDEN RA, DANDLIKER PS, LILLEBY KE, MEYERS JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988: 109: 783-788.
80. SCHMIDT GM, KOVACS A, ZAIA JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988: 46: 905-907.
81. EMANUEL D, CUNNINGHAM I, JULES-ELYSEE K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988: 109: 777-782.
82. LJUNGMAN P, ENGELHARD D, LINK H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992: 14: 831-835.
83. GERNA G, ZAVATTONI M, BALDANTI F, et al. Circulating cytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. J Med Virol 1998: 55: 64-74.
84. SALZBERGER B, MYERSON D, BOECKH M. Circulating CMV-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection. J Infect Dis 1997: 176: 778-781.
85. Anonymous. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group [published erratum appears in N Engl J Med 1992 Apr 23;326(17):1172] [see comments]. N Engl J Med 1992: 326: 213-220.
86. REED EC, WOLFORD JL, KOPECKY KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 1990: 112: 505-510.
87. LJUNGMAN P, CORDONNIER C, EINSELE H, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients; A report from the european group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1998: 21: 473-476.
88. DREW WL, MINER RC, BUSCH DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991: 163: 716-719.
89. BALDANTI F, UNDERWOOD MR, STANAT SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996: 70: 1390-1395.
90. SLAVIN MA, BINDRA RR, GLEAVES CA, PETTINGER MB, BOWDEN RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrobial Agents Chemotherapy 1993: 37: 1360-1363.
91. REUSSER P, CORDONNIER C, EINSELE H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996: 17: 813-817.
92. ERICE A, BORRELL N, LI W, MILLER WJ, BALFOUR HH JR. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998: 178: 531-534.
93. BOECKH M, ZAIA JA, JUNG D, SKETTINO S, CHAUNCEY TR, BOWDEN RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation [In Process Citation]. Biol Blood Marrow Transplant 1998: 4: 13-19.
94. LEWIS RA, CARR LM, DOYLE K, et al. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS - the hpmpc peripheral cytomegalovirus retinitis trial - a randomized, controlled trial. Ann Intern Med 1997: 126: 264 ff.
95. LJUNGMAN P, LAMBERTENGHI DELILIERS G, HOLLER E, et al. The use of cidofovir in allogeneic SCT recipients: results of an EBMT retrospective survey. 25th Annual Meeting European Group for Blood and Marrow Transplantation, 1999, Vol. Abstract EX 10, Hamburg.
96. BACIGALUPO A, BREGANTE S, TEDONE E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996: 62: 376-380.
97. WALTER EA, GREENBERG PD, GILBERT MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor [see comments]. N Engl J Med 1995: 333: 1038-1044.
98. MCLAUGHLIN-TAYLOR E, PANDE H, FORMAN SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994: 43: 103-110.
99. GERNA G, FURIONE M, BALDANTI F, PERCIVALLE E, COMOLI P, LOCATELLI F. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Haematol 1995: 91: 674-683.
100. HOLMBERG LA, BOECKH M, HOOPER H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (in press).